{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:21:27Z","timestamp":1754486487528,"version":"3.40.4"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-114916"],"award-info":[{"award-number":["MOP-114916"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fonds de la recherche en sant\u00e9 du Qu\u00e9bec","award":["#23247"],"award-info":[{"award-number":["#23247"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.pnpbp.2014.07.006","type":"journal-article","created":{"date-parts":[[2014,7,19]],"date-time":"2014-07-19T18:15:37Z","timestamp":1405793737000},"page":"27-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys"],"prefix":"10.1016","volume":"56","author":[{"given":"Nicolas","family":"Morin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Morissette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th\u00e9r\u00e8se","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2014.07.006_bb0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0006-8993(99)01224-X","article-title":"Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release","volume":"825","author":"Aghajanian","year":"1999","journal-title":"Brain Res"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0015","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1002\/mds.870040514","article-title":"Biochemistry of Parkinson's disease 28years later: a critical review","author":"Agid","year":"1989","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fnsys.2011.00048","article-title":"The 5-HT(2A) receptor antagonist M100907 produces antiparkinsonian effects and decreases striatal glutamate","volume":"5","author":"Ansah","year":"2011","journal-title":"Front Syst Neurosci"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/syn.20195","article-title":"Effects of sarizotan on the corticostriatal glutamate pathways","volume":"58","author":"Antonelli","year":"2005","journal-title":"Synapse"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0030","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.20370","article-title":"Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease","volume":"20","author":"Bara-Jimenez","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0035","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0040","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yfrne.2009.04.003","article-title":"Protective actions of ovarian hormones in the serotonin system of macaques","volume":"30","author":"Bethea","year":"2009","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0045","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.25366","article-title":"Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia","volume":"28","author":"Bezard","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0050","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-3565(24)35003-7","article-title":"Differing effects of N-methyl-d-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys","volume":"290","author":"Blanchet","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0055","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbrc.2010.09.110","article-title":"Dopamine D2 and 5-hydroxytryptamine 5-HT((2)A) receptors assemble into functionally interacting heteromers","volume":"401","author":"Borroto-Escuela","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0060","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/0024-3205(96)00449-3","article-title":"A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines","volume":"59","author":"Bryant","year":"1996","journal-title":"Life Sci"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0065","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1471-4159.2005.03600.x","article-title":"The 5-HT(1A) receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors","volume":"96","author":"Calcagno","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0070","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/mds.10343","article-title":"Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications","volume":"18","author":"Calon","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0075","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0080","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0079-6123(08)00922-9","article-title":"Serotonin\u2013dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias","volume":"172","author":"Carta","year":"2008","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0014-2999(85)90473-X","article-title":"High and low affinity [3H]imipramine binding sites in control and parkinsonian brains","volume":"117","author":"Cash","year":"1985","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0090","first-page":"S122","article-title":"Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications","volume":"47","author":"Chase","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0095","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0306-4522(93)90240-G","article-title":"Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram","volume":"54","author":"Chinaglia","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0100","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0306-4522(97)00445-4","article-title":"Gonadal hormones modulate 5-hydroxytryptamine 2A receptors: emphasis on the rat frontal cortex","volume":"83","author":"Cyr","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0105","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0026-895X(25)13392-0","article-title":"Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles","volume":"33","author":"Darchen","year":"1988","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0110","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.brainresbull.2005.12.009","article-title":"Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease","volume":"69","author":"Dekundy","year":"2006","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0115","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.expneurol.2011.02.012","article-title":"Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats","volume":"229","author":"Dupre","year":"2011","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0120","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0893-133X(97)00127-9","article-title":"Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity","volume":"18","author":"Farber","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0130","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.22473","article-title":"Serotonin and Parkinson's disease: on movement, mood, and madness","volume":"24","author":"Fox","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0135","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/1098-2396(20010315)39:4<288::AID-SYN1011>3.0.CO;2-V","article-title":"Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys","volume":"39","author":"Frechilla","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/(SICI)1098-2396(19990601)32:3<153::AID-SYN2>3.0.CO;2-X","article-title":"Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys","volume":"32","author":"Goulet","year":"1999","journal-title":"Synapse"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0145","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00702-008-0098-4","article-title":"Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats","volume":"115","author":"Gravius","year":"2008","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0150","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","article-title":"Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys","volume":"15","author":"Gregoire","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0155","first-page":"13","article-title":"Brain monoamines and parkinsonism","author":"Hornykiewicz","year":"1975","journal-title":"Natl Inst Drug Abuse Res Monogr Ser"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0160","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pneurobio.2011.08.004","article-title":"The serotonergic system in Parkinson's disease","volume":"95","author":"Huot","year":"2011","journal-title":"Prog Neurobiol"},{"issue":"207","key":"10.1016\/j.pnpbp.2014.07.006_bb0170","first-page":"e209","article-title":"Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque","volume":"33","author":"Huot","year":"2012","journal-title":"Neurobiol Aging"},{"issue":"115","key":"10.1016\/j.pnpbp.2014.07.006_bb0175","first-page":"e194","article-title":"5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with l-DOPA","volume":"33","author":"Huot","year":"2012","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0165","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of l-DOPA-induced dyskinesia in Parkinson's disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0180","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","article-title":"In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\\ increased motor disability","volume":"319","author":"Iravani","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0185","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1021\/jm00007a016","article-title":"Ketanserin analogues: the effect of structural modification on 5-HT2 serotonin receptor binding","volume":"38","author":"Ismaiel","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0190","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of l-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0195","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1046\/j.1471-4159.2001.00184.x","article-title":"Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation","volume":"76","author":"Kannari","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0200","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/archneur.60.9.1223","article-title":"Positron emission tomography of striatal serotonin transporters in Parkinson disease","volume":"60","author":"Kerenyi","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0205","first-page":"120","article-title":"Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease","volume":"131","author":"Kish","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0210","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0022-3565(24)36532-2","article-title":"Interactions of (+)- and (\u2212)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurons in rats","volume":"280","author":"Lejeune","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0215","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.nbd.2007.08.011","article-title":"Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease","volume":"29","author":"Levandis","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0220","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2004.04.028","article-title":"Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain","volume":"493","author":"Li","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0225","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/j.1471-4159.2009.06556.x","article-title":"l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia","volume":"112","author":"Lindgren","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0230","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1471-4159.2000.740693.x","article-title":"Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum","volume":"74","author":"Lucas","year":"2000","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0235","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.bbamcr.2010.08.010","article-title":"Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors","volume":"1803","author":"Lukasiewicz","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0240","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.brainres.2005.04.019","article-title":"Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA","volume":"1046","author":"Maeda","year":"2005","journal-title":"Brain Res"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0245","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0006-8993(00)03074-2","article-title":"Inhibition of evoked glutamate release by the neuroprotective 5-HT(1A) receptor agonist BAY x 3702 in vitro and in vivo","volume":"888","author":"Mauler","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0250","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00702-009-0231-z","article-title":"Aripiprazole in l-dopa-induced dyskinesias: a one-year open-label pilot study","volume":"116","author":"Meco","year":"2009","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0255","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","article-title":"Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease","volume":"101","author":"Mela","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0260","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","article-title":"The \u2018magic\u2019 of l-dopa: why is it the gold standard Parkinson's disease therapy?","volume":"26","author":"Mercuri","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0265","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuropharm.2012.07.036","article-title":"MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates","volume":"66","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0280","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.neuropharm.2013.05.028","article-title":"Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys","volume":"73","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0270","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.expneurol.2013.01.024","article-title":"Modeling dyskinesia in animal models of Parkinson disease","volume":"256","author":"Morin","year":"2014","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0275","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.neuropharm.2014.01.014","article-title":"Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys","volume":"79","author":"Morin","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0285","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/mds.20654","article-title":"Prevention of levodopa-induced dyskinesias by a selective NR1A\/2B N-methyl-d-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin","volume":"21","author":"Morissette","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0290","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1124\/jpet.108.138842","article-title":"In vivo characterization of a novel phenylisothiocyanate tropane analog at monoamine transporters in rat brain","volume":"326","author":"Murthy","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0295","series-title":"Parkinson's disease 2012","first-page":"1","article-title":"Imbalanced dopaminergic transmission mediated by serotonergic neurons in l-DOPA-induced dyskinesia","author":"Navailles","year":"2012"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0300","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0166-4328(96)00111-8","article-title":"Ca2+ mobilizing agents mimic serotonin 5-HT2A facilitation of N-methyl-d-aspartate depolarization","volume":"73","author":"Neuman","year":"1996","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0305","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1006\/exnr.2002.8009","article-title":"Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models","volume":"177","author":"Oh","year":"2002","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0310","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.neuropharm.2003.10.003","article-title":"5-HT2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat","volume":"46","author":"Olijslagers","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0315","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12031-008-9137-8","article-title":"Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias","volume":"38","author":"Ouattara","year":"2009","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0325","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.neuroscience.2010.03.022","article-title":"Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias","volume":"167","author":"Ouattara","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0320","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.neurobiolaging.2009.07.014","article-title":"Metabotropic glutamate receptor type 5 in levodopa-induced motor complications","volume":"32","author":"Ouattara","year":"2011","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0330","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1111\/j.1460-9568.2012.08243.x","article-title":"Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors","volume":"36","author":"Paquette","year":"2012","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0335","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0165-0173(94)00007-C","article-title":"Functional anatomy of the basal ganglia. I. The cortico-basal ganglia\u2013thalamo-cortical loop","volume":"20","author":"Parent","year":"1995","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0340","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.npp.1300819","article-title":"Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex","volume":"31","author":"Pehek","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0345","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0893-133X(01)00333-5","article-title":"5-HT2A and 5-HT2C\/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum","volume":"26","author":"Porras","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0350","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0014-2999(93)90109-U","article-title":"Activation of 5-HT2 receptors facilitates depolarization of neocortical neurons by N-methyl-d-aspartate","volume":"231","author":"Rahman","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0355","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1126\/science.285.5428.763","article-title":"Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants","volume":"285","author":"Ramamoorthy","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2014.05.003","article-title":"Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias","author":"Rascol","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0370","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/j.1460-9568.2011.07675.x","article-title":"Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias","volume":"33","author":"Riahi","year":"2011","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0365","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.neuint.2012.08.009","article-title":"Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain","volume":"61","author":"Riahi","year":"2012","journal-title":"Neurochem Int"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0375","series-title":"Parkinson's disease: current progress","first-page":"93","article-title":"Neurotransmitter receptors in the parkinsonian brain","author":"Rinne","year":"1980"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0380","first-page":"653","article-title":"ACP-103, a 5-HT2A receptor inverse agonist","volume":"7","author":"Roberts","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0385","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/(SICI)1096-9861(19991018)413:2<219::AID-CNE4>3.0.CO;2-F","article-title":"Subcellular distribution of 5-hydroxytryptamine2A and N-methyl-d-aspartate receptors within single neurons in rat motor and limbic striatum","volume":"413","author":"Rodriguez","year":"1999","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0390","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/mds.23179","article-title":"Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study","volume":"25","author":"Roselli","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0395","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0405","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0072-9752(07)83002-8","article-title":"Functional neurochemistry of the basal ganglia","volume":"83","author":"Samadi","year":"2007","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0400","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.neurobiolaging.2007.02.005","article-title":"mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys","volume":"29","author":"Samadi","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0410","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.neuropharm.2010.11.024","article-title":"Estradiol modulation of cortical, striatal and raphe nucleus 5-HT1A and 5-HT2A receptors of female hemiparkinsonian monkeys after long-term ovariectomy","volume":"60","author":"Sanchez","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0415","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pnpbp.2013.05.008","article-title":"Estradiol and brain serotonin reuptake transporter in long-term ovariectomized parkinsonian monkeys","volume":"45","author":"Sanchez","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0420","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1046\/j.1471-4159.1994.62041382.x","article-title":"Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine","volume":"62","author":"Schmidt","year":"1994","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0425","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/syn.890010103","article-title":"Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists","volume":"1","author":"Sprouse","year":"1987","journal-title":"Synapse"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0430","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0028-3908(88)90079-2","article-title":"Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: a comparative study with dorsal raphe neurons","volume":"27","author":"Sprouse","year":"1988","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0435","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/mds.25561","article-title":"AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study","volume":"28","author":"Stocchi","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-8993(96)00239-9","article-title":"Quantitative subregional distribution of serotonin1A receptors and serotonin transporters in the human dorsal raphe","volume":"727","author":"Stockmeier","year":"1996","journal-title":"Brain Res"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0445","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/2191-219X-3-44","article-title":"SERT-to-DAT ratios in early Parkinson's disease do not correlate with the development of dyskinesias","volume":"3","author":"Suwijn","year":"2013","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0450","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cne.902220208","article-title":"A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis)","volume":"222","author":"Szabo","year":"1984","journal-title":"J Comp Neurol"},{"author":"Addex Therapeutics","key":"10.1016\/j.pnpbp.2014.07.006_bb0005"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0455","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0460","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.nucmedbio.2010.01.006","article-title":"In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease","volume":"37","author":"Wang","year":"2010","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.pnpbp.2014.07.006_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(00)00213-2","article-title":"Antagonist activity of meta-chlorophenylpiperazine and partial agonist activity of 8-OH-DPAT at the 5-HT(7) receptor","volume":"396","author":"Wood","year":"2000","journal-title":"Eur J Pharmacol"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584614001389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584614001389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T21:48:38Z","timestamp":1746308918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584614001389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":93,"alternative-id":["S0278584614001389"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2014.07.006","relation":{},"ISSN":["0278-5846"],"issn-type":[{"type":"print","value":"0278-5846"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2014.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}